Search

Objective: The da Vinci SP® surgical system offers improvements and refinements for the robotic single-site procedures. Here, we report the first case performing the single-port robotic-assisted left lateral sectionectomy (LLS) for hepatic tumor using the da Vinci SP® surgical system, and demonstrate the safety and technical feasibility of this platform. Methods: A 69-year-old female patient with hepatic tumor underwent single-port robotic-assisted LLS using the da Vinci SP® system at the Chinese People's Liberation Army (PLA) General Hospital on December 27, 2021. And the clinical data, preoperative preparations, surgical procedures, and postoperative recovery of this patients were summarized. Results: The patient with hepatic tumor underwent successful single-port robotic-assisted LLS. The intraperitoneal operation time was 49 minutes and the estimated blood loss was 10 ml. No significant intraoperative complications were observed. The Visual Analogue Scale (VAS) pain intensity score was 3/10 in the immediate postoperative period and 1/10 on postoperative day one. The patient was discharged on postoperative day four. Conclusion: Herein, we report the first case of single-port robotic-assisted LLS for hepatic tumor using da Vinci SP® system, and this operation is technically safe and feasible. The present case indicated that the single-port robotic-assisted surgery is expected to further improve the application prospect of single-port surgery.

Objective: To report the first experience of performing the single-port robotic-assisted hepatic caudate lobectomy via the da Vinci SP® surgical system and demonstrate the safety and technical feasibility of this platform. Methods: A 30-year-old female patient with diagnosis of hepatic hemangioma underwent single-port robotic-assisted caudate lobectomy using the da Vinci SP® system at the Chinese People's Liberation Army (PLA) General Hospital on January 20, 2022. The clinical data, preoperative preparations, surgical procedures, and postoperative recovery of this patient were summarized. Results: The patient underwent single-port robotic-assisted hepatic caudate lobectomy successfully. The intraperitoneal operation time was 97 minutes, and the estimated blood loss was 20 ml. No significant intraoperative complications were observed. The Visual Analogue Scale (VAS) pain intensity score was 3/10 in the immediate postoperative period and 1/10 on postoperative day one. The patient was discharged on postoperative day 2. Conclusion: Herein, we report the first case of single-port robotic-assisted caudate lobectomy using da Vinci SP® system, and this operation in complicated hepatectomy is technically safe and feasible. The present case indicated that the single-port robotic-assisted surgery is expected to further improve the application prospect of single-port surgery.

Objective: To firstly report the single-port robotic-assisted pancreatectomy using the da Vinci SP system and demonstrate the technical feasibility of this platform. Methods: To summarize the clinical data, preoperative preparations, surgical procedures, and postoperative recovery of a female patient with pancreatic serous cystadenoma who underwent single-port robotic-assisted pancreatectomy using the da Vinci SP system in Chinese People’s Liberation Army (PLA) General Hospital on December 24, 2021. Results: The patient underwent successful single-port robotic-assisted pancreatectomy. The operation time was 55 minutes and the estimated blood loss was 20 ml. No significant intraoperative adverse events were observed. The Visual Analogue Scale (VAS) pain intensity score was 3/10 in the immediate postoperative period and 1/10 on postoperative day two. The patient was discharged on postoperative day three with a drainage tube after being confirmed by CT examination that there were no any surgical complications. Conclusion: In conclusion, we first report the single-port pancreatectomy with da Vinci SP system. The successful attempt indicated that the application of single-port robot in uncomplicated pancreas surgery is safe and feasible, but it still needs further clinical practice.